We previously showed a prolonged inhibition of current-induced vasodilation (CIV) after a single oral high-dose of aspirin. In this study, we tested the hypothesis of platelet involvement in CIV. Nine healthy volunteers took 75 mg aspirin/day, 98 mg of clopidogrel bisulfate/day, or placebo for 4 days.
INTRODUCTION
A significant increase in skin blood flow (SkBF) has been observed in response to non-noxious galvanic current application in humans. This current-induced vasodilation (CIV) has been described as the result of an axon reflex (3) and disappears in locally anaesthetized or chronically capsaicintreated skin. Then CIV depends on capsaicin sensitive fibers and is an interesting model of the neuro-vascular interaction following non-noxious stimulation (11, 16) . Prostaglandins are synthesized by cyclo-oxygenases (COX) and play a key role as mediators in the vascular response observed during CIV. COX are expressed in a large variety of human tissues including endothelium, smooth muscles, nerves and platelets (29). We recently reported a long lasting inhibition of CIV (>5 days) following a single high (1000mg) oral dose of aspirin (11, 12, 40) , which irreversibly blocks both isoforms of COX (COX-1 and COX-2). COX of neuronal origin does not seem responsible for this long lasting effect (13) . This long lasting inhibition of CIV is consistent with the time required to re-synthesize unblocked platelets after oral single dose aspirin leading to the hypothesis that platelets participate to the vascular response to CIV. Indeed, a single oral high dose of aspirin irreversibly inactivates the platelet COX pathway for the duration of the life of the platelets (~10 days) (1, 36) . Indomethacin, a non specific COX inhibitor devoid of effect on vanilloid receptors and acid-sensing ion channels (41), abolished CIV confirming that the inhibition of CIV by aspirin likely resulted from its effect on COX (and not on vanilloid receptors or on acid-sensing ion channels). Furthermore, the specific COX-2 inhibitor, celecoxib, failed to affect CIV, suggesting that CIV is mainly a COX-1-dependent phenomenon (39).
Together with the long lasting effect of a single oral high dose of aspirin, the fact that COX-1 isoform participates in CIV raises the question of a possible platelet involvement in the axon-reflex CIV.
Although there is, to date, no in-vivo proof of a direct platelet-mediated vasodilation in humans, the hypothesis of a platelet involvement in axon-reflex vasodilation and other vasodilator mechanisms has previously been explored in-vitro (15, 23, 31). Those authors provided evidence for a direct in-used to set light transmission to 0% and 100% respectively. Aggregation was measured as the slope of the aggregation after the addition of the agonist and expressed as percent total aggregation per second.
Aggregation responses were determined in 0.3 ml sample of platelet-rich plasma. Aggregation was stimulated with 2 and 1 µmol/L ADP (Helena, Claremont, Ontario, Canada) to test the ADP pathway and 0.3mg/ml arachidonic acid (Helena, Claremont, Ontario, Canada) to test the COX pathway.
With aspirin the inhibition of arachidonic acid-induced platelet aggregation is almost 100%, while with clopidogrel the inhibition of ADP-induced aggregation never reaches 100%, is dose-and timedependent, an at steady state is in the range of 40% to 60% (33). Then, the efficacy of treatments was defined as a decrease of at least 50% in platelet aggregation induced by arachidonic acid and as a decrease of at least 20% in platelet aggregation induced by ADP (as compared to their reference values) for aspirin and clopidogrel, respectively, as compared to individual baseline values. Patients not fulfilling these criteria were not enrolled in the study.
The aggregation study was not used to argue for the participation of platelets in microvascular responses but was aimed at confirming that any absence of drug effects on CIV was not related to an ineffective dose or to non-adherence of the volunteers in following the treatment regimen.
Protocol 1:
Nine healthy volunteers (7 males, 2 females), 27.6±2.8 [mean ± SD] years, height: 177.3±7.2 cm, weight: 68.9±7.4 kg were enrolled in the first protocol.
Treatments were started 4 days before each experiment. Subjects received aspirin, clopidogrel and placebo treatments in a double-blinded random order, with an interval of at least 3 weeks between drug treatments. The last capsule was taken at 7:00AM on the day of microvascular investigation.
Blood sample collections were performed at 9:00AM to assess platelet aggregation and drug efficiency. The microvascular studies for CIV were started between 9:10AM and 9:30AM. Thus, the last drug capsule intake took place approximately 2.25 hours before the start of the microvascular tests.
In order to avoid any local inflammatory effects of the venous puncture on CIV, assessment was performed on the arm contra-lateral to blood sampling.
Protocol 2:
We aimed to test whether any impairment of CIV seen in Protocol 1 resulted from an impairment of endothelium-dependent vasodilation by aspirin, although at such very low doses endothelial function was expected to be unimpaired. Previous studies have shown that, after aspirin intake, endothelial cells fully recover their cyclo-oxygenase activity within 24 hours (18, 19, 22) . Thus if any impairment of endothelial or smooth muscle COX had occurred despite the very low dose of aspirin used in Protocol 1, a 24-hour delay in the assessment of CIV would allow for the restoration of endothelial and smooth muscle cell cyclo-oxygenase activity, whereas platelet aggregation would continue to be inhibited. Therefore, in Protocol 2, we tested Acetylcholine (Ach)-mediated vasodilation and post-occlusive hyperhemia, and treatment intake was staggered earlier than in Protocol 1, beginning 5 days and stopping 26 hours before the experiment.
Ten healthy young men, 23.0 ±2.8 years, 179.2±5.1 cm, 73.4±9.2 kg, participated in this second protocol. Volunteers enrolled in the first protocol were not allowed to participate in protocol 2.
A first CIV test was performed before treatment. This first test was referred as the test "at enrollment" throughout the text, to avoid any confusion with the terminology for baseline values obtained in the first two minutes of each protocol. Subjects were then given either aspirin or placebo in a doubleblind manner.
Blood sample collections were performed at 9:00 AM to assess platelet aggregation and drug efficacy.
Microvascular investigations were started within half an hour of the blood sampling and performed on the contralateral arm to avoid any variation arising from potential inflammatory effects on the arm used for sampling.
Assessment of CIV (Protocols 1 and 2)
CIV assessments were performed in a quiet air-conditioned room with the ambient temperature set at 24±1°C. The subjects were placed supine and rested for 15-min prior to data collection. We studied the effect on SkBF of anodal current application, through deionized water, on the volar aspect of the forearm. This technique has been extensively described elsewhere (10). Two laser-Doppler multi-fiber probes were used and connected to a laser-Doppler flowmeter (Periflux PF4001, Perimed, Sweden). One probe ("active" probe: PF481.1, Perimed, Sweden) was specially designed to allow for SkBF measurements. The "active" probe has a circular chamber allowing for the positioning of an adhesive patch designed with a sponge of ~1.2 cm² area (PF383, Perimed, Sweden). Before each experiment the sponge was wet with 0.2 ml of deionized water and the patch, combined with the "active" probe, was fixed to the skin. The patch allowed for current application through the anodal terminal of a 9-V current intensity-regulated supplier (Periiont, Micropharmacology System, PF382 Perimed, Sweden). The cathodal terminal was connected to an Ag/AgCl disposable electrode (Care 610, Kendall, Neustadt, Germany) fixed 5 cm from "active" probe. The second laser Doppler probe ("reference" probe: PF408, Perimed, Sweden), positioned on the same volar aspect of the skin forearm, was used to assess the stability of SkBF at an adjacent un-stimulated site. The current application consisted of the transcutaneous delivery of two consecutive 1-min periods of 0.1-mA anodal current separated by a 10-min interval. The first current application is known to induce little vasodilator response whereas the second current application induces an ample aspirin sensitive vasodilation (11) . Following the second period of current application, data were recorded for 10 min.
Assessment of endothelial function (protocol 2 only)
Simultaneously to CIV testing, an additional identical laser-Doppler multifiber probe was used to assess ACh-mediated vasodilation (PF481.1, Perimed, Sweden). The technique has been described elsewhere (26, 44). The sponge of the electrode (PF383, Perimed, Sweden) was wet with 0.2 ml of ACh solution (2% in deionized water), followed by an anodal stimulation (9V, 0.08 mA/cm², 20 s, Periiont, Micropharmacology System, PF382 Perimed, Sweden). The cathodal electrode (Care 610, Kendall, Neustadt, Germany) was placed 5 cm from the anodal electrode.
For the second protocol, a tourniquet was placed proximal to the position of the electrodes. It was used to cause three minutes of ischemia of the forearm by applying supra-systolic pressure for 3 minutes.
Ischemia was started 10 minutes after the end of the second period of anodal current application and post-occlusive hyperemia recorded for an additional 15 minutes. This was used to assess the maximal values during reperfusion, which has been shown to reflect endothelial function within an individual across a treatment period in a reproducible manner (45).
Pressure measurement
Throughout the experiments systemic arterial blood pressure was recorded using a Finapres 2350 (Ohmeda, Englewood CO, USA) positioned on the 2 nd or 3 rd finger of the hand contra-lateral to the sites of SkBF measurements.
Recordings & Data analysis
The signals from the laser-Doppler flowmeters and Finapress were recorded on a computer via an analog to digital converter (Biopac System, Inc., California) with a sample frequency of 20 Hz.
Data collection started with a 2-min baseline period before the onset of current application. For CIV, we analyzed the maximal vascular conductance recorded following the second period of current application. For ACh iontophoresis, we studied both: the peak conductance (immediately after stimulation) and the plateau conductance (20 minutes later), since we previously reported that the plateau, but not peak, was prostaglandin dependent (14) . For post-occlusive hyperemia we recorded the peak value for vascular conductance following deflation of the occlusion cuff.
Statistical analyses
To detect a decrease of CIV from 600 %C b to 200 %C b with 150 SD, power calculations indicated that the minimal number of subjects to be enrolled for = 0.05 and a 80% power was 6. 
RESULTS:
PROTOCOL 1
Assessment of platelet aggregation
As shown in table 1, aspirin treatment induced a complete abolition of the arachidonic acid-induced platelet aggregation as compared to placebo, but had no significant effect on the 2 and 1 µmol/L ADP-induced platelet aggregation. Clopidogrel treatment induced a significant decrease of the 2 and 1 µmol/L ADP-induced platelet aggregation (on the average -48 to -70% from value at enrollment). A significant decrease of ~50% in the aggregation to arachidonic-acid was also noted.
No significant difference was found between the values for platelet aggregation observed under placebo and the values at enrollment.
Assessment of CIV
Compared with baseline values, no significant changes were observed for control SkBF at the reference probe or in mean arterial blood pressure during these experiments. No differences were found in vascular conductance values at rest: 0.12±0.03, 0.23±0.14 and 0.17±0.09 AU/mmHg among the placebo, aspirin, and clopidogrel trials, respectively. The two 1-min anodal current applications resulted in significant increases of SkBF corresponding to a CIV of: 822±314, 313±144 and 746±397
%C b with placebo, aspirin, and clopidogrel, respectively (p<0.01 vs. rest) as shown in Figure 1 . The CIV observed following aspirin treatment was less than the one observed following both placebo and clopidogrel (p<0.05). The CIV after clopidogrel was not significantly different from placebo (p=0.923).
PROTOCOL 2 Assessment of platelet aggregation
As shown in Table 2 , aspirin treatment induced a complete abolition of the arachidonic acid-induced platelet aggregation in 6 subjects. In the other four subjects the arachidonic acid-induced platelet aggregation was severely impaired (~10% of the value at enrollment), which seems consistent with the ~10% re-synthesis of platelets after one day without aspirin intake. When compared with placebo and the values at enrollment, the effect of aspirin on arachidonic acid-induced platelet aggregation was significant (p<0.05). Placebo showed no difference from the values at enrollment.
Assessment of CIV
Compared with baseline values, no significant changes were observed either for control SkBF at the reference probe or for mean arterial blood pressure during these experiments. In the CAPRIE study, clopidogrel was found to have a significant benefit over low-dose aspirin, specifically in PAD patients in term of cardiovascular complications (5). More recently, an inhibitory effect of aspirin but not clopidogrel on arteriogenesis has been shown (20) . A relationship of these results to the preservation under clopidogrel but not under aspirin of neurovascular interactions involving platelets is a fascinating but unproven hypothesis for future studies.
Last, our results are of potential clinical significance. Low-dose aspirin is largely used in primary prevention among patients with high risk of cardiovascular disease. There is a high correlation between neuropathy and foot ulcer in diabetic patients. The inhibitory effect of aspirin, even at a very low dose, on the neurovascular response to primary afferent fiber activation could be a major disadvantage of this drug in such patients.
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